Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

20th Apr 2021 12:17

Avacta Group PLC - Yorkshire-based drug and medical equipment maker - Lateral flow test for Covid-19 is shown to have 98% sensitivity in clinical study. 20-minute AffiDX test correctly identified 96 out of 98 positive samples of virus and 101 out of 102 negative samples. Test effective on a range of viral loads. Company will file for a CE mark in May and start commercial roll-out in coming months.

Current stock price: 261.69 pence, up 12% on Tuesday

Year-to-date change: more than doubled from 114p on December 31

By Ivan Edwards; [email protected]

Copyright 2021 Alliance News Limited. All Rights Reserved.


Related Shares:

Avacta Group
FTSE 100 Latest
Value8,809.74
Change53.53